Company news

China Resources Double-crane Pharmaceutical Co., Ltd. Class A (SSE:600062) news

China Resources Double-crane Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: "China Resources Double-Crane Pharmaceutical Co.…

China Resources Double-crane Pharmaceutical Co., Ltd. Class A (SSE:600062) news

Press releases & updates

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining the Approval Notice for Marketing Application of the Chemical API Brexpiprazole by the Controlled Subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.

(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Progress in Major Asset Restructuring

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Propranolol Hydrochloride Injection of the Wholly-owned Subsidiary China Resources Zizhu Pharmaceutical Co., Ltd. Passing the Consistency Evaluation of Quality and Efficacy for Generic Drugs

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets by the Wholly-owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd.

"China Resources Double-Crane Pharmaceutical Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining the Drug Registration Certificate for Lomustine Capsules

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on the Obtaining of the Drug Registration Certificate for Oxcarbazepine Tablets by the Controlled Subsidiary, China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Progress in Major Asset Restructuring

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on the Profit Distribution Plan for the First Half of 2026

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on the Obtaining of the Drug Registration Certificate for Lidocaine Hydrochloride Gel

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Sodium Lactate Ringer's Irrigation Solution by Wholly-owned Subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd.

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Receipt of the Notice of Approval for Clinical Trial of DC7001A Capsules by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Acetazolamide Sustained‑release Capsules by the Controlled Subsidiary Henan Zhongshuai Pharmaceutical Sci & Tech Co., Ltd.

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Completion of the Phase III Clinical Trial of Pregabalin Sustained-Release Tablets by Wholly-owned Subsidiary China Resources Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd.

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Repurchase of Relevant Rights and Interests in Perfluoropropane Lipid Microsphere Injection by the Partner

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on the Proposed Selection of Certain Drugs of the Company in the National Centralized Drug Procurement

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Implementation of Dividend Distribution for 2025

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Participation in the Public Bidding for Shares of Lier Chemical Co., Ltd.

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Progesterone Soft Capsules by Wholly-owned Subsidiary Shanxi Jinxin Double-Crane Pharmaceutical Co., Ltd.

"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtainment of CEP Certificate for Sodium Valproate API by Holding Subsidiary China Resources Double-Crane Pharmaceutical (Hunan) Co., Ltd.

Announcement on Progress in Acquiring 100% Equity in Nanjing Xinbai Pharmaceutical Co., Ltd. and Completion of Industrial and Commercial Change Registration

Announcement on Obtaining Drug Registration Certificate for Some Drugs by Subsidiary

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Renewing Engagement of Accounting Firm

Announcement on Wholly-owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Ezetimibe Tablets

Announcement on Wholly-owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Sodium, Potassium, Magnesium and Calcium Concentrated Solution for Injection

Announcement on Completion of Phase III Drug Clinical Trial

Announcement on Acquiring 100% Equity of Nanjing Xinbai Pharmaceutical Co., Ltd. and Related Party Transactions

Announcement on ObtainingApproval Notice for the Supplementary Application of Drug for Dienogest Tablets by Wholly-owned Subsidiary China Resources Zizhu Pharmaceutical Co., Ltd.

Announcement on Convening the Q1 2026 Performance Briefing

Announcement on Lifting Sales Restrictions and Circulation of Restricted Stocks in 3rd Lifting Period of Initially Granted Part under Restricted Stock Incentive Plan of 2021

Announcement on Obtaining Approval Notice for Drug Supplement Application by Wholly-Owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. for Mannitol Injection

Announcement on Changing Registered Capital and Amending the Articles of Association

Announcement on Obtaining Drug Registration Certificate for Sodium Valproate Oral Solution by Holding Subsidiary Hunan Xiangzhong Pharmaceutical Co., Ltd.

Announcement on Convening the 2025 Annual Performance Briefing

Announcement on Implementing Repurchase and Cancellation under 2021 Restricted Stock Incentive Plan

Announcement on Wholly-owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Sodium Acetate Ringer's Injection

Announcement on Wholly-owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. Obtaining Drug Registration Certificate for Balanced Salt Irrigation Solution

Announcement on Drugs Being Selected for National Procurement Continuation After the Expiry of Agreement

Announcement on Resolutions of the 17th Meeting of the 10th Board of Directors

Announcement on Wholly-owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Compound Sodium Acetate Ringer's Injection

Announcement on Obtaining Approval from China Securities Regulatory Commission for the Public Issuance of Corporate Bonds to Professional Investors

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Obtaining Notice of Approval for Drug Supplementary Application for Pediatric Compound Amino Acid Injection (19AA-I-SF)

Announcement on Obtaining FDA Implied License for Drug Clinical Trials for DC6001 Tablets by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.

Announcement on Wholly-owned Subsidiary Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd. Passing GMP Compliance Inspection

Announcement on Completion of Fund Filing for Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II

Announcement on Completion of Fund Filing for the Establishment of Double-Crane Industry Fund

Announcement on Hydroxocobalamin Injection Obtaining Notice of Approval for Drug Clinical Trial